Pharmaceutical Executive Daily: New Research on Ozempic
Welcome to Pharmaceutical Executive Daily, your quick briefing on the top news shaping the pharmaceutical and life sciences industry.
Key News
- FDA approval of Bayer’s Lynkuet for menopausal hot flashes.
- New research suggesting Ozempic may reduce biological age.
- Novartis’ $12 billion merger agreement to acquire Avidity Biosciences.
Lynkuet Approval
The FDA has approved Bayer’s Lynkuet, also known as elinzanetant, as the first dual neurokinin 1 and 3 receptor antagonist for the treatment of moderate to severe vasomotor symptoms associated with menopause.
The approval is based on Phase III OASIS trial data showing significant reductions in hot flash frequency and severity.
As a non-hormonal option, Lynkuet provides an important new therapeutic alternative for patients seeking relief from menopausal symptoms without estrogen exposure.
Author's summary: New research on Ozempic and Lynkuet approval.